EnhydrisPECorp
Long/short equity, research analyst, biotech, healthcare

Acorda Therapeutics: 40% Upside Potential With Limited Downside Risk

The biotech sector appears to be in the midst of a classic equity bubble, with hype, instead of fundamentals, driving stock prices. To be specific, there are a number of mid-cap biotechs with no revenue to speak of, and deficits reaching into the billions, that have recently attained multi-billion dollar market caps based solely on the "potential" of their flagship drug candidates. And when these drugs do finally reach the market, fundamentals kick into overdrive, acting like a black hole on share prices. Arena Pharmaceuticals (NASDAQ:ARNA), Avanir Pharmaceuticals (NASDAQ:AVNR) Dendreon (NASDAQ:DNDN), Horizon Pharma (NASDAQ:HZNP) are just a few examples of this widespread phenomenon in the biotech sector.

With all the hype surrounding ...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details